DÄ internationalArchive20/2020The neurofibromatoses

Review article

The neurofibromatoses

Dtsch Arztebl Int 2020; 117: 354-60. DOI: 10.3238/arztebl.2020.0354

Farschtschi, S; Mautner, V; Lawson McLean, A C; Schulz, A; Friedrich, R E; Rosahl, S K

For technical reasons, the English full text will be published approximately two weeks after the German print edition has been published.

Neurofibromatose-Ambulanz, Klinik und Poliklinik für Neurologie, Universitätsklinikum Hamburg-Eppendorf: Dr. med. Said Farschtschi, Prof. Dr. med. Victor-Felix Mautner
Klinik für Neurochirurgie, Neurofibromatosezentrum, Helios Klinikum Erfurt:
Dr. med. Anna Cecilia Lawson McLean, Prof. Dr. med. Steffen K. Rosahl
Leibniz-Institut für Alternsforschung, Fritz-Lipmann-Institut (FLI), Jena:
Dr. med. Dr. rer. nat. Alexander Schulz
Klinik und Poliklinik für Mund-, Kiefer- und Gesichtschirurgie, Universitätsklinikum
Hamburg-Eppendorf: Prof. Dr. med. Dr. med. dent. Reinhard E. Friedrich
1.Blakeley JO, Plotkin SR: Therapeutic advances for the tumors associated with neurofibromatosis type 1, type 2, and schwannomatosis. Neuro Oncol 2016; 18: 624–38 CrossRef MEDLINE PubMed Central
2.Kehrer-Sawatzki H, Farschtschi S, Mautner VF, Cooper DN: The molecular pathogenesis of schwannomatosis, a paradigm for the co-involvement of multiple tumour suppressor genes in tumorigenesis. Hum Genet 2017; 136: 129–48 CrossRef MEDLINE PubMed Central
3.Hirbe AC, Gutmann DH: Neurofibromatosis type 1: a multidisciplinary approach to care. Lancet Neurol 2014; 13: 834–43 CrossRef
4.DeBella K, Szudek J, Friedman JM: Use of the national institutes of health criteria for diagnosis of neurofibromatosis 1 in children. Pediatrics 2000; 105: 608–14 CrossRef MEDLINE
5.Mautner V-F, Lindenau M, Kaufmann D: Klinik und Genetik der Neurofibromatose. Dtsch Arztebl 1995; 92: A1759–64.
6.Agaimy A, Vassos N, Croner RS: Gastrointestinal manifestations of neurofibromatosis type 1 (Recklinghausen‘s disease): clinicopathological spectrum with pathogenetic considerations. Int J Clin Exp Pathol 2012; 5: 852–62.
7.Listernick R, Louis DN, Packer RJ, Gutmann DH: Optic pathway gliomas in children with neurofibromatosis 1: consensus statement from the NF1 Optic Pathway Glioma Task Force. Ann Neurol 1997; 41: 143–9 CrossRef MEDLINE
8.Huson SM, Compston DA, Clark P, Harper PS: A genetic study of von Recklinghausen neurofibromatosis in south east Wales. I. Prevalence, fitness, mutation rate, and effect of parental transmission on severity. J Med Genet 1989; 26: 704–11.
9.Evans DG, Baser ME, McGaughran J, Sharif S, Howard E, Moran A: Malignant peripheral nerve sheath tumours in neurofibromatosis 1. J Med Genet 2002; 39: 311–4 CrossRef MEDLINE PubMed Central
10.Levine TM, Materek A, Abel J, O‘Donnell M, Cutting LE: Cognitive profile of neurofibromatosis type 1. Semin Pediatr Neurol 2006; 13: 8–20 CrossRef MEDLINE
11.Tucker T, Schnabel C, Hartmann M, et al.: Bone health and fracture rate in individuals with neurofibromatosis 1 (NF1). J Med Genet 2009; 46: 259–65 CrossRef MEDLINE
12.Dombi E, Baldwin A, Marcus LJ, et al.: Activity of selumetinib in neurofibromatosis type 1-related plexiform neurofibromas. N Engl J Med 2016; 375: 2550–60 CrossRef MEDLINE PubMed Central
13.Lin AL, Gutmann DH: Advances in the treatment of neurofibromatosis-associated tumours. Nat Rev Clin Oncol 2013; 10: 616–24 CrossRef MEDLINE
14.Kresak JL, Walsh M: Neurofibromatosis: a review of NF1, NF2, and schwannomatosis. J Pediatr Genet 2016; 5: 98–104 CrossRef MEDLINE PubMed Central
15.Hexter J, Jones A, Joe H, et al.: Clinical and molecular predictors of mortality in neurofibromatosis 2: a UK national analysis of 1 192 patients. J Med Genet 2015; 52: 699–705 CrossRef MEDLINE
16.Asthagiri AR, Parry DM, Butman JA, et al.: Neurofibromatosis type 2. Lancet 2009; 373: 1974–86 CrossRef
17.Schulz A, Büttner R, Hagel C, et al.: The importance of nerve microenvironment for schwannoma development. Acta Neuropathol 2016; 132: 289–307 CrossRef MEDLINE PubMed Central
18.Morrison H, Sperka T, Manent J, Giovannini M, Ponta H, Herrlich P: Merlin/neurofibromatosis type 2 suppresses growth by inhibiting the activation of Ras and Rac. Cancer Res 2007; 67: 520–7 CrossRef MEDLINE
19.Petrilli AM, Fernández-Valle C: Role of Merlin/NF2 inactivation in tumor biology. Oncogene 2016; 35: 537–48 CrossRef MEDLINE PubMed Central
20.Evans DGR, Ramsden RT, Shenton A, et al.: Mosaicism in neurofibromatosis type 2: an update of risk based on uni/bilaterality of vestibular schwannoma at presentation and sensitive mutation analysis including multiple ligation-dependent probe amplification. J Med Genet 2007; 44: 424–8 CrossRef MEDLINE PubMed Central
21. Stivaros SM, Stemmer-Rachamimov AO, Alston R, et al.: Multiple synchronous sites of origin of vestibular schwannomas in neurofibromatosis Type 2. J Med Genet 2015; 52: 557–62 CrossRef MEDLINE PubMed Central
22.Dewan R, Pemov A, Kim HJ, et al.: Evidence of polyclonality in neurofibromatosis type 2-associated multilobulated vestibular schwannomas. Neuro Oncol 2015; 17: 566–73 CrossRef MEDLINE PubMed Central
23.Samii M, Matthies C: Management of 1 000 vestibular schwannomas (acoustic neuromas): hearing function in 1 000 tumor resections. Neurosurgery 1997; 40: 248–60; discussion 260–2 CrossRef MEDLINE
24.Slattery WH, Fisher LM, Hitselberger W, Friedman RA, Brackmann DE: Hearing preservation surgery for neurofibromatosis Type 2-related vestibular schwannoma in pediatric patients. J Neurosurg 2007; 106: 255–60 CrossRef MEDLINE
25.Rasmussen R, Claesson M, Stangerup SE, et al.: Fractionated stereotactic radiotherapy of vestibular schwannomas accelerates hearing loss. Int J Radiat Oncol Biol Phys 2012; 83: e607–11 CrossRef MEDLINE
26.Plotkin SR, Merker VL, Halpin C, et al.: Bevacizumab for progressive vestibular schwannoma in neurofibromatosis type 2: a retrospective review of 31 patients. Otol Neurotol 2012; 33: 1046–52 CrossRef MEDLINE
27.Best SR, Ahn J, Langmead S, et al.: Voice and swallowing dysfunction in neurofibromatosis 2. Otolaryngol Head Neck Surg 2018; 158: 505–10 CrossRef MEDLINE
28.Evans DG, Huson SM, Donnai D, et al.: A clinical study of type 2 neurofibromatosis. Q J Med 1992; 84: 603–18.
29.Evans DG, Birch JM, Ramsden RT: Paediatric presentation of type 2 neurofibromatosis. Arch Dis Child 1999; 81: 496–9 CrossRef MEDLINE PubMed Central
30.Wentworth S, Pinn M, Bourland JD, et al.: Clinical experience with radiation therapy in the management of neurofibromatosis-associated central nervous system tumors. Int J Radiat Oncol Biol Phys 2009; 73: 208–13 CrossRef MEDLINE
31.Hagel C, Stemmer-Rachamimov AO, Bornemann A, et al.: Clinical presentation, immunohistochemistry and electron microscopy indicate neurofibromatosis type 2-associated gliomas to be spinal ependymomas. Neuropathology 2012; 32: 611–6 CrossRef MEDLINE
32.Plotkin SR, O‘Donnell CC, Curry WT, Bove CM, MacCollin M, Nunes FP: Spinal ependymomas in neurofibromatosis type 2: a retrospective analysis of 55 patients. J Neurosurg Spine 2011; 14: 543–7 CrossRef MEDLINE
33.Farschtschi S, Merker VL, Wolf D, et al.: Bevacizumab treatment for symptomatic spinal ependymomas in neurofibromatosis type 2. Acta Neurol Scand 2016; 133: 475–80 CrossRef MEDLINE
34.Lawson McLean AC, Rosahl SK: Growth dynamics of intracranial tumors in patients with neurofibromatosis type 2. World Neurosurg 2017; 98: 152–61 CrossRef MEDLINE
35.Lawson McLean AC, Rosahl SK: Growth dynamics of intramedullary spinal tumors in patients with neurofibromatosis type 2. Clin Neurol Neurosurg 2016; 146: 130–7 CrossRef MEDLINE
36.Hagel C, Lindenau M, Lamszus K, Kluwe L, Stavrou D, Mautner VF: Polyneuropathy in neurofibromatosis 2: clinical findings, molecular genetics and neuropathological alterations in sural nerve biopsy specimens. Acta Neuropathol 2002; 104: 179–87 CrossRef MEDLINE
37.Bäumer P, Mautner VF, Bäumer T, et al.: Accumulation of non-compressive fascicular lesions underlies NF2 polyneuropathy. J Neurol 2013; 260: 38–46 CrossRef MEDLINE
38.Schulz A, Baader SL, Niwa-Kawakita M, et al.: Merlin isoform 2 in neurofibromatosis type 2-associated polyneuropathy. Nat Neurosci 2013; 16: 426–33 CrossRef MEDLINE
39.Evans DG, Bowers NL, Tobi S, et al.: Schwannomatosis: a genetic and epidemiological study. J Neurol Neurosurg Psychiatry 2018; 89: 1215–9 CrossRef MEDLINE
40.Piotrowski A, Xie J, Liu YF, et al.: Germline loss-of-function mutations in LZTR1 predispose to an inherited disorder of multiple schwannomas. Nat Genet 2014; 46: 182–7 CrossRef MEDLINE PubMed Central